The central mechanism of risperidone-induced hyperprolactinemia

Sun, Weiwei; LinYu, Li; Huang, Xu‐Feng; Shi, Yan‐Chuan; Yang, Huifeng; Zhang, Song; Lin, Shu

doi:10.1016/j.pnpbp.2017.03.009

Cited by 6 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At present, clinical trials have successfully proved that the PGD can significantly reduce the symptoms of hyperprolactinemia caused by antipsychotic drugs [ 19 ]. However, the majority of the studies focused on the hyperprolactinemia induced by Risperidone, Sulpiride, and Olanzapine [ 28 – 30 ]; the data describing the Amisulpride-induced hyperprolactinemia were rare, which may be associated with its infrequent use in clinic. Meanwhile, the domestic investigation showed that Aripiprazole is effective in high PRL caused by Risperidone, but ineffective in that induced by Amisulpride [ 31 , 32 ].…”

Section: Discussionmentioning

confidence: 99%

Effect of Peony-Glycyrrhiza Decoction on Amisulpride-Induced Hyperprolactinemia in Women with Schizophrenia: A Preliminary Study

Yang¹,

Yang³

et al. 2017

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Objective The aim of this study is to observe the effect of Peony-Glycyrrhiza Decoction (PGD) on hyperprolactinemia in women with schizophrenia induced by Amisulpride. Material and Methods A total of 41 female schizophrenia patients receiving Amisulpride were randomly divided into placebo (n = 20) and PGD groups (n = 21). Maintaining the original Amisulpride dose, the two groups were given placebo and PGD, respectively. The levels of Prolactin (PRL) and other hormones were measured on the initial day and at weeks 4 and 8 after treatment. Changes of clinical symptoms in patients with hyperprolactinemia were observed. The PANSS scores were recorded to assess the psychotic symptoms. Results Compared with placebo group, level of PRL decreased while Progesterone increased remarkably in the PGD group at weeks 4 and 8 (p < 0.01), and level of Estradiol in the PGD group increased significantly at week 8 (p < 0.05). There were no differences in PANSS scores and biochemical indexes between two groups at weeks 4 and 8. Conclusion PGD can improve symptoms of hyperprolactinemia and hormone levels in women with schizophrenia caused by Amisulpride, without affecting their mental symptoms and biochemical indexes.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of Peony-Glycyrrhiza Decoction on Amisulpride-Induced Hyperprolactinemia in Women with Schizophrenia: A Preliminary Study

Yang¹,

Yang³

et al. 2017

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

show abstract

“…Compared to first‐generation antipsychotics, second‐generation antipsychotics cause fewer extra‐pyramidal problems, but they present new challenges because they often lead to metabolic disorders. For example, risperidone increases food intake and induces weight gain, glucose intolerance, hypertriglyceridemia, and hyperprolactinemia . Previous research has suggested that risperidone induces weight gain by upregulating the expression of hypothalamic histaminergic H1 receptors and neuropeptide Y (NPY) .…”

Section: Introductionmentioning

confidence: 99%

Risperidone stimulates food intake and induces body weight gain via the hypothalamic arcuate nucleus 5‐HT2c receptor—NPY pathway

et al. 2019

Self Cite

View full text Add to dashboard Cite

Aims: Many patients taking risperidone for the treatment of psychiatric disorders experience substantial body weight gain. Researchers have speculated that risperidone induces obesity by modulating central signals; however, the precise central mechanisms involved remain to be fully elucidated.Methods: Twenty-four C57BL/6J mice were divided into four groups: a control group; a risperidone-treated group; a lorcaserin-treated group; and a combined risperidone + lorcaserin-treated group. The mice were received the corresponding treatments for 4 weeks, and their brains were collected for in situ hybridization analysis. A subset of C57BL/6J mice was administrated with risperidone or placebo, and brains were collected 60 minutes post-treatment for determination of c-fos activity. In addition, brains of NPY-GFP mice treated with or without risperidone were collected to perform colocalization of NPY and c-fos, as well as NPY and 5-HT2c receptor using immunohistochemistry. Results:There was significantly elevated c-fos expression in the hypothalamic arcuate nucleus (Arc) of risperidone-treated mice. More than 68% c-fos-positive neurons were NPY-expressing neurons. Furthermore, in situ hybridization revealed that Arc NPY mRNA expression was significantly increased in the risperidone-treated group compared with control group. Moreover, we identified that 95% 5-HT2c receptors were colocalized with NPY positive neurons, and increased Arc NPY mRNA expression induced by risperidone was markedly reduced by cotreatment with lorcaserin, a specific 5-HT2c receptor agonist. Conclusion:Our findings provide critical insight into the mechanisms underlying antipsychotic-induced obesity, which may assist the development of therapeutic strategies to address metabolic side effects of risperidone. K E Y W O R D S5-HT2c receptor, hypothalamic arcuate nucleus (Arc), NPY, obesity, risperidone

show abstract

“…A dose-response relationship between greater risk and larger cumulative dosage of the antipsychotics was also found, but the clinical implication of the findings was limited in light of the small hazards and the possibility of residual confounding. Among second-generation antipsychotics, risperidone has been examined as a possible risk factor for developing breast cancer because of its strong anti-dopaminergic profile which increases the risk of hyperprolactinemia [ 10 ]. In two previous nationwide population-based studies, there was no increased risk of breast cancer in risperidone users compared to individuals prescribed another atypical antipsychotics or a typical antipsychotic [ 11 , 12 ].…”

Section: Introductionmentioning

confidence: 99%

Risk of Breast Cancer in Association with the Use of Second-generation Antipsychotics

Joo

Lee

et al. 2022

Clin Psychopharmacol Neurosci

View full text Add to dashboard Cite

Objective: Previous studies regarding the relationship between the risk of breast cancer (BC) and antipsychotics use have reported inconsistent findings. Insufficient sample size and/or observation period may have hindered revealing the risk of BC associated with antipsychotics use. We aimed to investigate whether the use of second-generation antipsychotics (SGA) is associated with increased risk of BC. Methods: We used the Health Insurance Review Agency database in South Korea between 2008 and 2018. The index date was determined as the date of the first antipsychotic prescription. We selected women prescribed SGAs for more than 30 days within a year from the index date and age-matched controls, yielding 498,970 cases and 997,940 controls. The Cox proportional hazards regression model was used for estimating the risk. Results: The incidence rates of BC were 109.74 and 101.51 per 100,000 person-years in the case and control groups, respectively. There was an increased risk of BC in the case group (hazard ratio [HR] = 1.08, 95% confidence interval [CI] 1.04−1.13). There was a higher risk of BC in subjects prescribed with ≥ 10,000 mg of olanzapine equivalent dose (HR = 1.29, 95% CI 1.14−1.46) than those with ＜ 10,000 mg (HR = 1.05, 95% CI 1.00−1.11). The increased risk of BC in the case group became significant after six years of the observation period (≥ 6 years: HR = 1.24, 95% CI 1.14−1.35, 3 to ＜ 6 years: HR = 1.06, 95% CI 0.97−1.15, ＜ 3 years: HR = 1.02, 95% CI 0.95−1.09). Conclusion: This study indicated that the use of SGAs is associated with increased risk of BC in a long-term relationship with a dose-response pattern.

show abstract

The central mechanism of risperidone-induced hyperprolactinemia

Cited by 6 publications

References 29 publications

Effect of Peony-Glycyrrhiza Decoction on Amisulpride-Induced Hyperprolactinemia in Women with Schizophrenia: A Preliminary Study

Effect of Peony-Glycyrrhiza Decoction on Amisulpride-Induced Hyperprolactinemia in Women with Schizophrenia: A Preliminary Study

Risperidone stimulates food intake and induces body weight gain via the hypothalamic arcuate nucleus 5‐HT2c receptor—NPY pathway

Risk of Breast Cancer in Association with the Use of Second-generation Antipsychotics

Contact Info

Product

Resources

About